[First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell carcinoma (SWITCH-2 - AN 33/11)].

Subjects

Subjects :

Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols adverse effects
Carcinoma, Renal Cell mortality
Carcinoma, Renal Cell pathology
Disease Progression
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Germany
Humans
Indazoles
Kidney Neoplasms mortality
Kidney Neoplasms pathology
Male
Middle Aged
Niacinamide administration & dosage
Niacinamide adverse effects
Phenylurea Compounds adverse effects
Pyrimidines adverse effects
Sorafenib
Sulfonamides adverse effects
Survival Rate
Young Adult
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Carcinoma, Renal Cell drug therapy
Kidney Neoplasms drug therapy
Niacinamide analogs & derivatives
Phenylurea Compounds administration & dosage
Pyrimidines administration & dosage
Sulfonamides administration & dosage

Details

Language :

German

ISSN :

1433-0563

Volume :

53

Issue :

5

Database :

MEDLINE

Journal :

Der Urologe. Ausg. A

Publication Type :

Academic Journal

Accession number :

24727992

Full Text :

https://doi.org/10.1007/s00120-014-3459-7